According to the Pharmaceutical Research and Manufacturers of America, as many as 241 blood cancer medications are undergoing clinical development or FDA assessment, 98 of which are dedicated to lymphoma treatment, while 97 are for leukemia, 52 target multiple myeloma and 24 address bone marrow, blood and lymph node malignancies.
Report shows 241 blood cancer drugs in the pipeline
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||